UC appeals decision that both parties in CRISPR-Cas9 lawsuit can maintain patents
The University of California filed an appeal April 12 to overturn the US Patent Trial and Appeal Board’s, or PTAB’s, decision that there was no interference between the university’s and the Broad’s patent applications for CRISPR-Cas9 gene-editing technology.